Novonesis increases its full year 2026 organic sales growth outlook from 5-7% to now 7-8% based on a stronger performance so far in the year and the expectations for the rest of the year. Following the stronger sales growth outlook, the adjusted EBITDA margin is now expected to be at the higher end of the 37-38% range.
The H1 2026 announcement will be announced on August 19, 2026.
Publication of inside information pursuant to Market Abuse Regulation, Article 17.
Attachment
